Cambrex Expands Small-Scale Capacity at Iowa Facility
PTSM: Pharmaceutical Technology Sourcing and Management
The company has completed a small-scale capacity expansion at its site in Charles City, IA.
On Nov. 8, 2017, Cambrex announced the completion of a small-scale capacity expansion at its Charles City, IA, site. The expansion includes the installation of two 500-gallon glass-lined reactors and a third small-scale work center.
“Small-scale manufacturing has been identified as being a crucial area where capacity is at a premium within the industry, and this investment has been undertaken to increase our flexibility and reduce potential project bottle necks to benefit our customers,” said Joe Nettleton, vice president of US operations at Cambrex, in a company press release.
This investment comes after the installation of a new pilot plant at the site in 2017 and recent announcements of expansions across other manufacturing sites, including the construction of a $24-million, 4500-ft2 highly potent active pharmaceutical ingredient manufacturing facility at the Charles City site, which is due to open in 2019.
Source: Cambrex
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.
